ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021
Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium.
Open access · bronzeAbstract readMulticenter Study
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 157 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
157citing papers in PubMed, 2 pooled it
21.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
157 citing papers in PubMed, 2 syntheses or guidelines pooled it, 202 citations in OpenAlex.
- Cancer in Multilineage Mosaic RASopathies due to Pathogenic Variants in HRAS or KRAS: A Systematic Review and Meta-analysis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Pooled it
- Cancer in Costello syndrome: a systematic review and meta-analysis.British journal of cancer · 2023Pooled it
- Radiation Therapy Dose Escalation Failed to Improve Local Control for Intermediate-Risk Rhabdomyosarcoma on ARST1431: A Report From the Children's Oncology Group.International journal of radiation oncology, biology, physics · 2025Trial
- Event-free survival in relapsed and refractory rhabdomyosarcoma treated on cooperative group phase II trials: A report from the Children's Oncology Group.Pediatric blood & cancer · 2024Trial
- Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group.The Lancet. Oncology · 2024Trial
- Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.JCO precision oncology · 2024Trial
- Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- Omitting Bone Marrow Sampling in FDG-Avid Rhabdomyosarcoma With 2-[Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Observational
- Current Evidence for Circulating Tumor DNA in Sarcoma: Challenges and Opportunities for Clinical Application.Journal of surgical oncology · 2026Review
- Pediatric sarcomas: challenges and opportunities.Genes & development · 2026Review
- Head and Neck Rhabdomyosarcoma in Children: An Otolaryngological Perspective on Diagnostic and Therapeutic Approaches.Current oncology reports · 2026Review
- Catalase Defines Radiotherapy Resistance and a Therapeutic Vulnerability in Rhabdomyosarcoma.International journal of molecular sciences · 2026Article
- Evaluation of Prognostic Factors in Adult Sinonasal Rhabdomyosarcoma With Consideration of Resection Status.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026Article
- Paediatric Therapeutic Development Workshop on rhabdomyosarcoma.British journal of cancer · 2026Review
- Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers.Cell reports. Medicine · 2026Article
- Unraveling the dual roles of MICAL2 in skeletal muscle physiology and fusion negative rhabdomyosarcoma tumor progression.Cell death & disease · 2026Article
- System for study of diverse cellular composition in alveolar rhabdomyosarcoma.Scientific reports · 2026Article
- Core transcriptional regulatory circuitry identified from patient-derived tumor cells provides a specific vulnerability for rhabdomyosarcoma.Cell death & disease · 2026Article
- MYOD1 mutation drives cancer stem cell pathways and therapy-resistance in spindle cell/sclerosing rhabdomyosarcoma.Nature communications · 2026Article
97 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
32 authors at 11 institutions in 2 countries.
Jack F ShernGenetics Branch, Oncogenomics Section, Center for Cancer Research, National Institutes of Health, Bethesda, MD.ORCID 0000-0001-5579-7625
Joanna SelfeSarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0002-9556-3628
Elisa IzquierdoMolecular Diagnostics Department, The Institute of Cancer Research and Clinical Genomics, The Royal Marsden NHS Foundation, London, United Kingdom.
Rajesh PatidarGenetics Branch, Oncogenomics Section, Center for Cancer Research, National Institutes of Health, Bethesda, MD.ORCID 0000-0003-3578-8208
Hsien-Chao ChouGenetics Branch, Oncogenomics Section, Center for Cancer Research, National Institutes of Health, Bethesda, MD.
Young K SongGenetics Branch, Oncogenomics Section, Center for Cancer Research, National Institutes of Health, Bethesda, MD.
Marielle E YohePediatric Oncology Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD.
Sivasish SindiriGenetics Branch, Oncogenomics Section, Center for Cancer Research, National Institutes of Health, Bethesda, MD.
Jun WeiGenetics Branch, Oncogenomics Section, Center for Cancer Research, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-4812-0250
Xinyu WenGenetics Branch, Oncogenomics Section, Center for Cancer Research, National Institutes of Health, Bethesda, MD.
Erin R RudzinskiDepartment of Laboratories, Seattle Children's Hospital, University of Washington, Seattle, WA.
Donald A BarkauskasDepartment of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA.ORCID 0000-0002-2339-719X
Tammy LoChildren's Oncology Group, Monrovia, CA.
David HallChildren's Oncology Group, Monrovia, CA.ORCID 0000-0003-1257-2316
Corinne M LinardicDuke University School of Medicine, Durham, NC.
Debbie HughesPaediatric Tumour Biology, Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom.
Sabri JamalMolecular Diagnostics Department, The Institute of Cancer Research and Clinical Genomics, The Royal Marsden NHS Foundation, London, United Kingdom.
Meriel JenneyCardiff and Vale UHB, Paeds Oncology, Cardiff, United Kingdom.
Julia ChisholmChildren and Young People's Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.ORCID 0000-0003-3479-7997
Rebecca BrownSarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
Kristine JonesCancer Genomics Research Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD.
Belynda HicksCancer Genomics Research Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD.ORCID 0000-0001-8014-4888
Paola AngeliniChildren and Young People's Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.ORCID 0000-0001-5930-3530
Sally GeorgePaediatric Tumour Biology, Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0003-2777-4922
Louis CheslerPaediatric Tumour Biology, Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0001-7842-2068
Michael HubankMolecular Diagnostics Department, The Institute of Cancer Research and Clinical Genomics, The Royal Marsden NHS Foundation, London, United Kingdom.ORCID 0000-0002-2901-0742
Anna KelseyDepartment of Paediatric Histopathology, Manchester University NHS Foundation Trust Royal Manchester Childrens Hospital, Manchester, United Kingdom.
Susanne A GatzSarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0002-6438-9778
Stephen X SkapekDivision of Hematology/Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX.
Douglas S HawkinsDepartment of Pediatrics, Seattle Children's Hospital, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA.ORCID 0000-0003-3602-1375
Janet M ShipleySarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
Javed KhanGenetics Branch, Oncogenomics Section, Center for Cancer Research, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-5858-0488
Institute of Cancer Research · GBNational Institutes of Health · USRoyal Marsden NHS Foundation Trust · GBChildren's Oncology Group · USLeidos (United States) · USSeattle Children's Hospital · USCardiff and Vale University Health Board · GBDuke University · USManchester University NHS Foundation Trust · GBThe University of Texas Southwestern Medical Center · USUniversity of Southern California · US
Funding
NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6MCOG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5MCOG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8MChildren's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI DEVIDAS, MEENAKSHI · 2003 to 2013
$67.5MTherapy Resistance Mechanisms for CancerZIABC010998 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KHAN, JAVED · 2009 to 2025
$14.5MTargeting FGFR4, RAS, and PAX3-FOXO1 gene in RhabdomyosarcomaZIABC010999 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KHAN, JAVED · 2009 to 2025
$14.0MBIOINFORMATICS: SYSTEMS BIOLOGY OF PEDIATRIC CANCERSZIABC011002 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KHAN, JAVED · 2009 to 2025
$9.3MTargeting High-risk Neuroblastoma using high through put siRNA screeningZIABC010806 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KHAN, JAVED · 2009 to 2025
$7.8MGenomic characterization and development of therapies for RhabdomyosarcomaZIABC011722 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SHERN, JOHN · 2016 to 2025
$6.8MPredicting Response Prognosis in Pediatric CancersZIASC010366 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI KHAN, JAVED · 2009 to 2025
$4.7MCancer Research UK 25354Cancer Research UK C5066/A10399NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899
Abstract
purposeRhabdomyosarcoma is the most common soft tissue sarcoma of childhood. Despite aggressive therapy, the 5-year survival rate for patients with metastatic or recurrent disease remains poor, and beyond PATIENTS AND
methodsTumor samples collected from patients enrolled on Children's Oncology Group trials (1998-2017) and UK patients enrolled on malignant mesenchymal tumor and RMS2005 (1995-2016) trials were subjected to custom-capture sequencing. Mutations, indels, gene deletions, and amplifications were identified, and survival analysis was performed.
resultsDNA from 641 patients was suitable for analyses. A median of one mutation was found per tumor. In
conclusionThis is the largest genomic characterization of clinically annotated rhabdomyosarcoma tumors to date and provides prognostic genetic features that refine risk stratification and will be incorporated into prospective trials.
Indexed as
Gene AmplificationGene DeletionGenomicsINDEL MutationAdolescentAdultBiomarkers, TumorChildChild, PreschoolDatabases, GeneticDisease ProgressionDNA Mutational AnalysisFemaleGene Expression ProfilingGenetic Predisposition to DiseaseHumansBiomarkers, Tumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.